ID | 1123 |
Name of the vaccine | MENVEO |
Microbe | Bacteria |
Disease name | Meningococcal disease |
Name of bacteria | Neisseria meningitidis |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 2 months to 55 years |
Description of the vaccine | Meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine. |
Name of the manufacturer | GSK Vaccines |
Name of the manufacturing country | Sovicille (SI), Italy |
Year of manufacture | 2010 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative diplococcus. |
Efficacy | NA |
Vaccine formulation | Lyophilized MenA conjugate vaccine component reconstituted with MenCYW-135 liquid conjugate vaccine component. |
Dosage | Primary Vaccination -
2 months children : 4-dose series at 2, 4, 6, and 12 months of age.
Children initiating vaccination at 7 months through 23 months : 2-dose series.
Individuals (2 year-55 years) : a single dose of 0.5 ml.
Booster - single booster dose individuals aged 15 to 55 years after 4 years.
|
Mechanism of action | Production of bactericidal antibodies against the capsular polysaccharides of serogroups A, C, Y, and W-135. |
Route of administration | Intramuscular |
Indications | To prevent invasive meningococcal caused by Neisseria meningitidis serogroups A, C, Y and W-135. It does not prevent N meningitidis serogroup B disease. |
Export | Distributed by - GlaxoSmithKline |
Approval | US FDA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | For children- tenderness, injection site pain, erythema, irritability, sleepiness, persistent crying , change in eating habits, vomiting, diarrhoea, malaise and headache.
Adolescents and adults- injection site pain, headache, myalgia, malaise, nausea. |
Post vaccination | NA |
Dose type | Both |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/78514/download |
Other name | NA |
Additional Links | NA
|